Showing results (1-10 of 295) with videos related to
Sort By:
Pageof 30
Clinical and Translational Medicine|May 6, 2017
ETS-targeted therapy: can it substitute for MEK inhibitors?Osamu Tetsu, Frank McCormickCancer Cell|April 5, 2003
Proliferation of cancer cells despite CDK2 inhibitionOsamu Tetsu, Frank McCormickProceedings of the National Academy of Sciences of the United States of America|July 8, 2015
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 functionJanyaporn Phuchareon, Frank McCormick, David W Eisele, et al.Molecular & Cellular Oncology|June 17, 2016
ETS1 inactivation causes innate drug resistance to EGFR inhibitorsOsamu Tetsu, Janyaporn Phuchareon, David W Eisele, et al.Pharmacological Research|October 11, 2015
AKT inactivation causes persistent drug tolerance to EGFR inhibitorsOsamu Tetsu, Janyaporn Phuchareon, David W Eisele, et al.Chemotherapy|February 25, 2016
Drug Resistance to EGFR Inhibitors in Lung CancerOsamu Tetsu, Matthew J Hangauer, Janyaporn Phuchareon, et al.Human Molecular Genetics|November 6, 2007
Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic optionsThanaset Senawong, Janyaporn Phuchareon, Osamu Ohara, et al.Plos One|January 6, 2007
A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferationHiroshi Okabe, Sang-Hyun Lee, Janyaporn Phuchareon, et al.Translational Oncology|December 16, 2014
Fatty Acid binding protein 7 is a molecular marker in adenoid cystic carcinoma of the salivary glands: implications for clinical significanceJanyaporn Phuchareon, Jonathan B Overdevest, Frank McCormick, et al.Translational Oncology|November 13, 2014
c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary GlandsJanyaporn Phuchareon, Annemieke van Zante, Jonathan B Overdevest, et al.Pageof 30